Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Jan;65(1):1–12. doi: 10.1016/S0011-393X(04)90000-8

Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study

Mark H Gotfried 1,2, Rose Jung 3, Chad R Messick 4, Israel Rubinstein 2, Kevin W Garey 5, Keith A Rodvold 2, Larry H Danziger 2,∗
PMCID: PMC4052968  PMID: 24936100

Abstract

Background: Although corticosteroids such as prednisone are efficacious for the treatment of severe asthma, chronic administration of oral corticosteroid therapy is associated with significant adverse effects. Previous studies have shown that clarithromycin is effective in reducing bronchial hyperresponsiveness and allergen-induced bronchoconstriction. However, the effect of long-term clarithromycin therapy in patients with prednisone-dependent asthma is uncertain.

Objective: This study was conducted to determine the effects of oral clarithromycin on prednisone daily dosage, pulmonary function, quality of life (QOL), and asthmatic symptoms in patients with corticosteroid-dependent asthma.

Methods: This 14-week, prospective, randomized, double-blind, placebo-controlled pilot study was conducted at Pulmonary Associates (Phoenix, Arizona) and the University of Illinois at Chicago Medical Center (Chicago, Illinois). Patients aged 18 to 75 years with an established diagnosis of asthma and who had been receiving ≥5 mg/d of prednisone for the preceding 6 months were enrolled. After a 4-week data-collection period, patients received clarithromycin 500 mg BID for 6 weeks, followed by a 4-week follow-up period. The effects of clarithromycin therapy on prednisone dosage requirements, pulmonary function (as assessed using spirometry), QOL, and asthmatic symptoms (nocturnal asthma, shortness of breath, chest discomfort, wheezing, and cough) were assessed.

Results: Fourteen patients (9 men, 5 women; mean [SD] age, 62 [13] years) completed the study and were included in the final analysis. One patient withdrew from the study due to clarithromycin-related nausea. After 6 weeks of clarithromycin therapy, patients were able to tolerate a significant reduction in mean (SD) prednisone dosage from baseline (30% [18%]; P- 0.020). Pulmonary function, QOL, and asthmatic symptoms did not significantly worsen despite reduction in prednisone dose. All patients who completed the study tolerated clarithromycin therapy.

Conclusions: In this pilot study of patients with corticosteroid-dependent asthma, 6-week clarithromycin 500 mg BID was clinically effective in allowing a reduction in prednisone dosage, without worsening pulmonary function, QOL, or asthmatic symptoms. In addition, clarithromycin was well tolerated, with only 1 patient discontinuing therapy due to treatment-related nausea.

Keywords: clarithromycin, corticosteroid-dependent asthma, steroid-sparing effect, prednisone

Full Text

The Full Text of this article is available as a PDF (790.6 KB).

References

  • 1.National Asthma Education and Prevention program Expert Panel Report: Guidelines for the diagnosis and management of asthma update on selected topics—2002. J Allergy Clin Immunol. 2002;110(Suppl 5):S141–S219. [published correction appears in J Allergy Clin Immunol. 2003;111:466] [PubMed] [Google Scholar]
  • 2.American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987;136:225–244. doi: 10.1164/ajrccm/136.1.225. [DOI] [PubMed] [Google Scholar]
  • 3.Spahn J.D, Leung D.Y. 4th ed. Vol. 17. 1996. The role of glucocorticoids in the management of asthma; pp. 341–350. (Allergy Asthma Proc). [DOI] [PubMed] [Google Scholar]
  • 4.Zeiger R.S, Schatz M, Sperling W. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol. 1980;66:438–446. doi: 10.1016/0091-6749(80)90003-2. [DOI] [PubMed] [Google Scholar]
  • 5.Nelson H.S, Hamilos D.L, Corsello P.R. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis. 1993;147:398–404. doi: 10.1164/ajrccm/147.2.398. [DOI] [PubMed] [Google Scholar]
  • 6.Kamada A.K, Hill M.R, Ikle D.N. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol. 1993;91:873–882. doi: 10.1016/0091-6749(93)90345-g. [DOI] [PubMed] [Google Scholar]
  • 7.Szefler S.J, Rose J.Q, Ellis E.F. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol. 1980;66:447–451. doi: 10.1016/0091-6749(80)90004-4. [DOI] [PubMed] [Google Scholar]
  • 8.Fost D.A, Leung D.Y, Martin R.J. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol. 1999;103:1031–1035. doi: 10.1016/s0091-6749(99)70175-2. [DOI] [PubMed] [Google Scholar]
  • 9.LaForce C.F, Szefler S.J, Miller M.F. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol. 1983;72:34–39. doi: 10.1016/0091-6749(83)90049-0. [DOI] [PubMed] [Google Scholar]
  • 10.Gil J.C, Cedillo R.L, Mayagoitia B.G, Paz M.D. Isolation of Mycoplasma pneumoniae from asthmatic subjects. Ann Allergy. 1993;70:23–25. [PubMed] [Google Scholar]
  • 11.Hahn D.L, Dodge R.W, Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA. 1991;266:225–230. [PubMed] [Google Scholar]
  • 12.Kudoh S, Azuma A, Yamamoto M. Improvement of survival in subjects with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829–1832. doi: 10.1164/ajrccm.157.6.9710075. [DOI] [PubMed] [Google Scholar]
  • 13.Tagaya E, Tamaoki J, Kondo M. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest. 2002;122:213–218. doi: 10.1378/chest.122.1.213. [DOI] [PubMed] [Google Scholar]
  • 14.MacLeod C.M, Hamid Q.A, Cameron L. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther. 2001;18:75–82. doi: 10.1007/BF02852391. [DOI] [PubMed] [Google Scholar]
  • 15.Miyatake H, Taki F, Taniguchi H. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest. 1991;99:670–673. doi: 10.1378/chest.99.3.670. [DOI] [PubMed] [Google Scholar]
  • 16.Pugh R.N, Murray-Lyon I.M, Dawson J.L. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  • 17.Cockcroft D.W, Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  • 18.Marks G.B, Dunn S.M, Woolcock A.J. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol. 1992;45:461–472. doi: 10.1016/0895-4356(92)90095-5. [DOI] [PubMed] [Google Scholar]
  • 19.Jenkins H.A, Cherniack R, Szefler S.J. A comparison of the clinical characteristics of children and adults with severe asthma. Chest. 2003;124:1318–1324. doi: 10.1378/chest.124.4.1318. [DOI] [PubMed] [Google Scholar]
  • 20.Garey K.W, Rubinstein I, Gotfried M.H. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest. 2000;118:1826–1827. doi: 10.1378/chest.118.6.1826. [DOI] [PubMed] [Google Scholar]
  • 21.Liu M.C, Proud D, Lichtenstein L.M. Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects. J Allergy Clin Immunol. 2001;108:29–38. doi: 10.1067/mai.2001.116004. [DOI] [PubMed] [Google Scholar]
  • 22.Culic O, Erakovic V, Parnham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429:209–229. doi: 10.1016/s0014-2999(01)01321-8. [DOI] [PubMed] [Google Scholar]
  • 23.Kikuchi T, Hagiwara K, Honda Y. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother. 2002;49:745–755. doi: 10.1093/jac/dkf008. [DOI] [PubMed] [Google Scholar]
  • 24.Spahn J.D, Fost D.A, Covar R. Clarithromycin potentiates glucocorticoid responsiveness in subjects with asthma: Results of a pilot study. Ann Allergy Asthma Immunol. 2001;87:501–505. doi: 10.1016/S1081-1206(10)62264-8. [DOI] [PubMed] [Google Scholar]
  • 25.Kraft M, Cassell G.H, Pak J. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: Effect of clarithromycin. Chest. 2002;121:1782–1788. doi: 10.1378/chest.121.6.1782. [DOI] [PubMed] [Google Scholar]
  • 26.Hahn D.L. Treatment of Chlamydia pneumoniae infection in adult asthma: A before-after trial. J Fam Pract. 1995;41:345–351. [PubMed] [Google Scholar]
  • 27.Kadota J, Mukae H, Ishii H. Long-term efficacy and safety of clarithromycin treatment in subjects with diffuse panbronchiolitis. Respir Med. 2003;97:844–850. doi: 10.1016/s0954-6111(03)00042-8. [DOI] [PubMed] [Google Scholar]
  • 28.Saiman L, Marshall B.C, Mayer-Hamblett N, Macrolide Study Group Azithromycin in subjects with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA. 2003;290:1749–1756. doi: 10.1001/jama.290.13.1749. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES